Milestone Pharmaceuticals Inc. saw a significant price increase of 39.42%, crossing above the 5-day SMA, following the announcement of FDA approval for its CARDAMYST nasal spray.
This surge is attributed to the FDA's approval of CARDAMYST, the first self-administered treatment for paroxysmal supraventricular tachycardia (PSVT) in over 30 years, which is expected to benefit over 2 million Americans. The approval allows patients to manage their condition at home, significantly improving their quality of life. Milestone is well-capitalized with $82.6 million in cash and a $75 million royalty purchase agreement, ensuring a rapid launch in Q1 2026.
The implications of this approval are substantial, as it positions Milestone Pharmaceuticals to capture a significant market share in the treatment of PSVT, potentially addressing a large patient population and enhancing its revenue prospects.
Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.910
Low
8.00
Averages
8.00
High
8.00
Current: 1.910
Low
8.00
Averages
8.00
High
8.00
Wells Fargo
Mohit Bansal
upgrade
$4 -> $8
2025-12-16
Reason
Wells Fargo
Mohit Bansal
Price Target
$4 -> $8
AI Analysis
2025-12-16
upgrade
Reason
Wells Fargo analyst Mohit Bansal raised the firm's price target on Milestone Pharmaceuticals to $8 from $4 and keeps an Overweight rating on the shares. The firm says Cardamyst's robust label, its reasonable pricing and management's launch strategy bode well for a strong launch. Wells continues to see upside potential to stock despite recent strong performance.
H.C. Wainwright
Brandon Folkes
Buy
upgrade
$5 -> $8
2025-12-15
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$5 -> $8
2025-12-15
upgrade
Buy
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Milestone Pharmaceuticals to $8 from $5 and keeps a Buy rating on the shares following the approval of Cardamyst for the treatment of paroxysmal supraventricular tachycardia. The shares at curet levels underappreciate the commercial opportunity of Cardamyst in PSVT, the analyst tells investors in a research note. H.C. Wainwright expects commercial outperformance and the re-initiation of the AFib-RVR trial to drive share momentum over the next 12 to 18 months.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MIST
Unlock Now
TD Cowen
analyst
Hold
to
Buy
upgrade
$8
2025-12-15
Reason
TD Cowen
analyst
Price Target
$8
2025-12-15
upgrade
Hold
to
Buy
Reason
As previously reported, TD Cowen upgraded Milestone Pharmaceuticals to Buy from Hold with an $8 price target after Cardamyst nasal spray was approved by the FDA for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. The label is clean with no market-limiting warnings or monitoring requirements, notes the analyst, who also points out that Cardamyst will be available in retail pharmacies in Q1 of 2026 with a wholesale acquisition cost of $1,649.
TD Cowen
Hold
to
Buy
upgrade
$8
2025-12-15
Reason
TD Cowen
Price Target
$8
2025-12-15
upgrade
Hold
to
Buy
Reason
TD Cowen upgraded Milestone Pharmaceuticals to Buy from Hold with an $8 price target.
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
